AIM ImmunoTech Inc. (NYSE American: AIM) announced it extended the maturity date of a promissory note with Streeterville Capital LLC to June 30, 2027, and reported an increase in stockholder equity to approximately $2.1 million as of March 31, 2026.

The company reported stockholder equity increased by approximately $11.9 million from a stockholder deficit of approximately $9.8 million as of December 31, 2025. AIM stated it has raised additional equity-generating funds through various transactions since March 31, 2026.

Under the amendment terms, the outstanding balance of the promissory note originally issued on February 16, 2024, is approximately $1.68 million following the extension fee. The previous maturity date was not specified in the company's announcement.

"We appreciate the continued support and confidence demonstrated by Streeterville Capital through this extension," said Chief Executive Officer Thomas Equels. "This amendment enhances our capital allocation flexibility at an important stage for the Company as we remain focused on executing our clinical and operational priorities."

AIM ImmunoTech focuses on developing Ampligen (rintatolimod) for treating late-stage pancreatic cancer. The company stated the financial changes support its ability to manage capital resources while maintaining focus on its pancreatic cancer development program and other initiatives.

The information was disclosed in a company press release statement.